Karsten Jürchott Selected Research

Karsten Jürchott Research Topics

Disease

9	Neoplasms (Cancer) 02/2024 - 01/2002
3	Virus Diseases (Viral Diseases) 01/2019 - 03/2008
3	Breast Neoplasms (Breast Cancer) 11/2005 - 01/2002
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 01/2019
2	Melanoma (Melanoma, Malignant) 02/2024 - 08/2002
2	COVID-19 01/2023 - 01/2022
2	Human Influenza (Influenza) 01/2017 - 07/2013
2	Colorectal Neoplasms (Colorectal Cancer) 12/2010 - 08/2005
1	Heart Failure 03/2024
1	Fibrosis (Cirrhosis) 03/2024
1	Neoplasm Metastasis (Metastasis) 02/2024
1	Brain Neoplasms (Brain Tumor) 02/2024
1	Disease Progression 02/2024
1	Inflammation (Inflammations) 02/2024
1	Myocardial Infarction 10/2023
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023
1	Coinfection 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Multiple Sclerosis 01/2022
1	Insulin Resistance 01/2020
1	Weight Loss (Weight Reduction) 01/2020
1	Immune System Diseases (Immune Disorders) 01/2019
1	Yellow Fever 11/2015
1	Infections 11/2015
1	Glioblastoma (Glioblastoma Multiforme) 03/2008
1	Glioma (Gliomas) 03/2008
1	Sarcoma (Soft Tissue Sarcoma) 08/2002

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 05/2005 - 01/2002
2	VaccinesIBA 01/2022 - 11/2015
2	Hemagglutinins (Hemagglutinin)IBA 01/2017 - 05/2005
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2004 - 01/2002
1	Extracellular Matrix ProteinsIBA 03/2024
1	InterferonsIBA 02/2024
1	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 02/2024
1	ARQ 197IBA 02/2024
1	Therapeutic UsesIBA 10/2023
1	LipidsIBA 01/2023
1	Glycoproteins (Glycoprotein)IBA 01/2023
1	Cadherins (E-Cadherin)IBA 11/2022
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	AntibodiesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	CytokinesIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2019
1	AntigensIBA 07/2013
1	CD40 Ligand (CD40L)IBA 07/2013
1	ChromatinIBA 12/2010
1	Mitogen-Activated Protein KinasesIBA 12/2010
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2010
1	Y-Box-Binding Protein 1IBA 12/2010
1	Phosphatidylinositol PhosphatesIBA 06/2010
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2005
1	Biomarkers (Surrogate Marker)IBA 08/2005
1	multidrug resistance-associated protein 1IBA 08/2002
1	Melphalan (Alkeran)FDA LinkGeneric 08/2002
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2002
1	Biological FactorsIBA 01/2002
1	Plasminogen Activator Inhibitor 1IBA 01/2002
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2002
1	Plasminogen InactivatorsIBA 01/2002

Therapy/Procedure

7	Therapeutics 03/2024 - 01/2004
3	Drug Therapy (Chemotherapy) 11/2005 - 01/2002
1	Radiotherapy 03/2008